Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Total Non-Current Liabilities (2016 - 2026)

Champions Oncology has reported Total Non-Current Liabilities over the past 16 years, most recently at $24.0 million for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities fell 3.34% year-over-year to $24.0 million; the TTM value through Jan 2026 reached $24.0 million, down 3.34%, while the annual FY2025 figure was $28.5 million, 3.09% up from the prior year.
  • Total Non-Current Liabilities for Q1 2026 was $24.0 million at Champions Oncology, down from $25.9 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $29.1 million in Q2 2023 and troughed at $24.0 million in Q1 2026.
  • A 5-year average of $26.4 million and a median of $26.6 million in 2022 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 41.92% in 2022 and later fell 12.59% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $26.6 million in 2022, then increased by 4.35% to $27.7 million in 2023, then fell by 12.59% to $24.2 million in 2024, then rose by 6.81% to $25.9 million in 2025, then fell by 7.12% to $24.0 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for CSBR at $24.0 million in Q1 2026, $25.9 million in Q4 2025, and $26.9 million in Q3 2025.